Background. Sarcopenia is common among older hospitalized adults but estimates vary according to definitions used. Aims of this study were to investigate the agreement between the European Working Group on Sarcopenia in Older People (EWGSOP2) and the Foundation for the National Institutes of Health (FNIH) Sarcopenia Project criteria and to compare the predictive value of both definitions for 3-year mortality.
INTRODUCTION
The aging process is characterized by a progressive decline in skeletal muscle mass, resulting in loss of muscle strength and function, condition that has been referred to as sarcopenia (1).
Sarcopenia is receiving an increasing interest in research and practice (2) due to its high prevalence, especially in nursing home or hospital setting (3) , and its association with mobility impairment, disability, loss of independence, poor quality of life, hospitalization, and death (4) . Furthermore, sarcopenia has been recently recognized as a specific disease entity, deserving its own ICD-10-CM code (M62.84) (5) .
However, one of the major obstacles in both research and clinical practice is the lack of consensus regarding the diagnostic criteria and the methods used to assess such a condition. The most widely used definitions of sarcopenia are those proposed by the European Working Group on Sarcopenia in Older People (EWGSOP) (6) and the Foundation for the National Institutes of Health (FNIH) Sarcopenia Project (7) . Despite handgrip strength and skeletal muscle mass are key features in all sarcopenia definitions, cut off values and techniques used to assess muscle mass and strength differ between definitions, resulting in a low concordance between FNIH and EWGSOP criteria (8) and, specifically, in a low positive percent agreement (PPA) where PPA was defined by Dam et al. as the proportion of participants who were categorized as having sarcopenia by both the FNIH criteria and EWGSOP divided by the number of participants who were categorized as having the condition by the second set of criteria (9) . Recently, the European Working Group updated the original definition in order to incorporate the new insights collected on the condition over the last decade, and proposed a new operational definition of sarcopenia, the EWGSOP2 (10).
So far, no data are available on the agreement between the new EWGSOP2 and the FNIH sarcopenia definitions. Moreover, it is unclear whether the different sarcopenia definitions have similar associations with clinical outcomes, such as mortality. The primary objective of this report A c c e p t e d M a n u s c r i p t was to investigate the agreement between EWGSOP2 and FNIH sarcopenia definitions in a sample of older patients admitted to 12 Geriatrics and Internal Medicine acute care wards in Italy, enrolled in the GLISTEN Study (11) . Furthermore, we sought to compare the predictive value of both definitions towards 3-year mortality.
METHODS

Study Design and Data Collection
Data were obtained from the Gruppo di Lavoro Italiano Sarcopenia -Trattamento E Nutrizione (GLISTEN) project, a cohort study performed in Geriatric and Internal Medicine acute care wards of 12 Italian hospitals (Monza, Turin, Ferrara, Verona, Parma, Florence, Ancona, Rome, Napoli I, Napoli II, Cagliari, Messina). Methodology of the GLISTEN project has been described in detail elsewhere (11) . Briefly, the study was designed to investigate the prevalence and clinical correlates of sarcopenia in older hospitalized patients in Italy and to estimate the incidence of sarcopenia during hospital stay. All study centers obtained ethical approval from their institutions; participants signed a written informed consent. All patients consecutively admitted to the participating wards from February 2014 and May 2014 were screened for enrollment. Exclusion criteria were age younger than 65 years and patient's unwillingness to take part in the study. All patients were assessed within 2 days since hospital admission and were followed until discharge. Participants' data were collected through a standardized dedicated questionnaire including demographic characteristics, self-report functional status, cognitive, and mood assessment; medication use; incident and prevalent medical conditions; and biochemical test results. Objective measures of muscle mass (bioimpedance analysis [BIA]) and physical performance (handgrip strength and 4-m usual walking speed) were obtained at hospital admission and before discharge. Survival status was recorded up to 36 months after hospital discharge. In this study, 45 of the original 655 enrollees were excluded because of some baseline missing data, leading to a final sample of 610 persons A c c e p t e d M a n u s c r i p t (mean age 80.7 ± 6.6 years, male 48.7%). Mortality data were available in 527 participants, who were therefore included in survival analyses.
Assessment of Sarcopenia
According to EWGSOP2 (10) and FNIH criteria (12) , sarcopenia was defined as presence of low muscle strength plus low muscle mass assessed at hospital admission.
Muscle strength was assessed by grip strength (GS), measured using a calibrated hand-held dynamometer (JAMAR hand dynamometer Model BK-7498, Fred Sammons Inc., Brookfield, IL).
According to Southampton protocol (13) , three trials for each hand were performed in sitting or supine position (14) , and the highest value of the strongest hand was used in the analyses. GS values below 27 kg in men and 16 kg in women were considered as abnormal according to the EWGSOP2 consensus (15). The corresponding cut-offs for the FNIH criteria were 26 kg and 16 kg for men and women, respectively (16) . (18) , and as a ASM/BMI ratio lower than 0.789 in men and 0.512 and women, according to FNIH (19).
Covariates
Sociodemographic variables (age, gender, smoking habits, education) were obtained through clinical interview at hospital admission. Cognitive functioning and functional status in six basic activities of daily living (ADL) were assessed as reported elsewhere (11) . Severe ADL disability was defined as the presence of difficulty in three or more activities (20) . 
Statistical analysis
Prevalence of sarcopenia was assessed using each algorithm; concordance between the two definitions was visually assessed with a mosaic plot of frequencies and quantitatively evaluated with Cohen's kappa coefficients. Kappa values, that is a measure of agreement corrected to take into account the amount of concordance due to chance, varies between 0 and 1 and can be interpreted as follows: 0-0.39 indicating minimal agreement, 0.40-0.59 as weak, 0.60-0.79 as moderate, ≥0.80 as strong agreement (23) A combination definition was also considered (neither criterion positive, only EWGSOP2 criterion positive, only FNIH criterion positive, both criteria).
Baseline characteristics were compared across the sarcopenia groups. Continuous variables distribution was visually inspected through histograms and normal qq-plot. Continuous data with approximately normal distribution were described as mean ± standard deviation and compared by ttest and one-way ANOVA. Median [interquartile range, IQR] and, accordingly, the Mann-Whitney U and Kruskal-Wallis tests, were used when the distribution deviated substantially from normal.
Categorical variables were summarized in terms of percentages and were compared by using the Pearson's chi squared test or the Fisher's exact test, as appropriate.
Crude mortality rates were estimated, and Kaplan-Meier curves were fitted to explore survival probabilities. The log-rank test and Cox regression analysis were used to assess the effect of sarcopenia on 3-year mortality. Three Cox models were hierarchically fitted: unadjusted, age and gender adjusted, and adjusted for other potential confounders (i.e. age, gender, SPMSQ, severe ADL disability, Charlson Comorbidity Index). 
Participants' baseline characteristics
One hundred thirty-nine participants ( Figure 1 shows agreement between the 2 sarcopenia definitions: out of the 220 participants who were classified as sarcopenic by at least one definition, agreement was obtained in only 65 (10.7%), whereas 12.1% were classified as sarcopenic by EWGSOP2 but not FNIH criterion and 13.3% as sarcopenic by FNIH but not EWGSOP2 criterion. Cohen's kappa coefficient was 0.29.
Agreement between EWGSOP2 and FNIH definitions
Compared to those deemed as non-sarcopenic by both definitions and those identified as sarcopenic by one but not the other, participants with agreement sarcopenia status were older, had greater prevalence of male, smokers and severe ADL disability ( Table 2) . Estimates derived from the Cox proportional hazard models ( 
Predictive value of EWGSOP2 and FNIH definitions
DISCUSSION
This study, performed in a cohort of older patients admitted to Geriatric and Internal Medicine acute care wards, showed that agreement between EWGSOP2 and FNIH definitions on the identification of sarcopenic patients is poor, therefore the two definitions cannot be used interchangeably. Both sarcopenia definitions were associated with increased 3-year mortality, although the EWGSOP2 seemed to have the best predictive value in terms of mortality.
Agreement between EWGSOP2 and FNIH definitions
Previous reports in which the original EWGSOP was compared to FNIH sarcopenia definition showed that the prevalence of such condition varied substantially when different diagnostic criteria were used (8, 9, 24) . Agreement was not improved in our study, where sarcopenia prevalence was A c c e p t e d M a n u s c r i p t similar among EWGSOP2 and FNIH definitions but, more importantly, the overlap between the two definitions was low (kappa statistics = 0.29).
EWGSOP2 and FNIH definitions have similar conceptual frameworks and both include measures of lean mass and strength. As previously explained by Dam and Colleagues (9), we believe that the lack of agreement between these two criteria is mainly explained by differences in the categorization of low muscle mass. On one hand, EWGSOP2 criteria recommend the utilization of ASM adjusted for height or ASM (12), on the other, FNIH criteria recommend to use ASM adjusted for BMI as first choice (10). As a result of that categorization, subjects identified as sarcopenic by EWGSOP2 criteria in the present study had lower average BMI, no case of obesity, higher prevalence of underweight (23.7%, data not shown), and higher rates of reported weight loss in the last 6 months, compared to those identified with FNIH criteria. Conversely, sarcopenic patients according to FNIH definition were characterized by high prevalence of obesity (31%, data not shown) and diabetes, with a negligible prevalence of underweight (2.7%, data not shown). As already commented, FNIH criteria seems to identify participants that, despite having high lean mass and high BMI, are functionally more impaired because are unable to generate enough muscular strength relative to their body mass (condition conceptualized as sarcopenic obesity) (9) .
EWGSOP2, as well as EWGSOP criteria, instead, seem to catch malnourished patients and, possibly, might include cachectic patients as previously investigated in the same sample (11) .
Predictive value of EWGSOP2 and FNIH definitions
Previous prospective studies have evaluated the validity of the original EWGSOP and FNIH criteria for predicting mortality in several settings (4, (25) (26) (27) , including acute care wards (24, 28 Cox regression analyses showed that sarcopenia, according to both definitions, represents an independent risk factor for mortality, even though statistical significance was reduced for FNIH definition after adjusting for comorbidity, cognitive status and disability. Furthermore, when the two definitions were combined, generating a four-group variable, only EWGSOP2 and EWGSOP2/FNIH combined group showed a significant independent risk of mortality. Although generalization of these findings should obviously be done with caution given the relatively small number of patients, our results suggest that EWGSOP2 might predict mortality better than FNIH definition in acutely hospitalized sarcopenic patients. However, the main finding that should be highlighted is that using each definition, we lost a share of sarcopenic subjects that are at increased risk mortality.
Clinical research has to progress in order to overcoming the discrepancy between sarcopenia definitions, and our study strongly supports the need not only of reaching general consensus in the criteria and cut-off values for sarcopenia to enable a comparison between studies, but, above all, to identify all the individuals at risk of complication related to sarcopenia.
Strength and limitations
Our study has several strengths. It is a large, multicenter, prospective cohort study involving Geriatric and Internal Medicine hospital units, thus providing easily generalizable information from the "real-world". Second, we explored the association between sarcopenia and mortality, which has been rarely investigated in a hospital setting. Third, this is the first study that investigated the predictive value of EWGSOP2 sarcopenia definition and compared EWGSOP2 and FNIH criteria in a hospital setting: thus, our results are of current interest for researchers and major relevance for clinicians. Nevertheless, in interpreting these findings, some limitations should be considered. First, we estimated appendicular muscle mass by BIA using Sergi equation instead of dual energy X-ray absorptiometry (DEXA), the technique that is recognized as the gold standard for the assessment of muscle mass. BIA measures are affected by the hydration status of patients, which admittedly change very rapidly in geriatric patients; nevertheless, this technique is inexpensive, easy to use, readily reproducible, and appropriate for bedridden patients, being therefore considered as an acceptable alternative to DEXA in a hospital setting (30).
Second, as previously described (11), the assessment of sarcopenia in acutely ill older patients might be affect by a transient impairment in muscle strength, unrelated to sarcopenia, but due to the systemic effect of the acute disease responsible for hospital admission, leading to a potential overestimation of the condition. Third, we cannot exclude that the association between sarcopenia and mortality is related to residual confounding, because data on some potential confounders (including admission diagnoses) were not collected. Fourth, this study was conducted on a cohort of hospitalized older people, therefore generalization of results to community dwelling or institutionalized older people is not possible. In this regard, further researches are needed to confirm the association between the two sarcopenia's phenotypes and mortality in these populations.
Finally, the evaluation of the prognostic utility of sarcopenia definition should include additional important clinical endpoints, including functional status and disability, not assessed in our work.
In summary, in this sample of Italian hospitalized geriatric patients, the agreement between EWGSOP2 and FNIH definitions was low, suggesting that these criteria cannot be used interchangeably. Diagnosis of sarcopenia on hospital admission was associated with increased risk A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t 
